Lucid Diagnostics (LUCD) Cash & Equivalents (2020 - 2026)

Lucid Diagnostics has reported Cash & Equivalents for 7 years, with the latest figure at $27.9 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 10.45% year-over-year to $27.9 million; the trailing twelve-month figure through Mar 2026 stood at $27.9 million (up 10.45% YoY), and the FY2025 full-year result was $34.7 million, up 55.22% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $27.9 million, down from $34.7 million in the prior quarter.
• The five-year high for Cash & Equivalents was $47.9 million in Q1 2022, with the low at $14.5 million in Q3 2024.
• Historically, Cash & Equivalents has averaged $29.3 million across 5 years, with a median of $26.9 million in 2022.
• The largest YoY upside for Cash & Equivalents was 126137.35% in 2022 against a maximum downside of 58.11% in 2022.
• Lucid Diagnostics' Cash & Equivalents stood at $22.5 million in 2022, then slipped by 15.92% to $18.9 million in 2023, then grew by 18.32% to $22.4 million in 2024, then jumped by 55.22% to $34.7 million in 2025, then declined by 19.68% to $27.9 million in 2026.
• The last three Cash & Equivalents figures came in at $27.9 million (Q1 2026), $34.7 million (Q4 2025), and $47.3 million (Q3 2025), per Business Quant data.